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Dengue Virus, 
Nepal
To the Editor: Dengue virus be-
longs to the genus Flavivirus, family 
Flaviviridae. It has 4 serotypes: den-
gue virus type 1 (DENV-1), dengue 
virus type 2 (DENV-2), dengue virus 
type 3 (DENV-3), and dengue virus 
type 4 (DENV-4). Dengue virus is 
maintained in a cycle between humans 
and Aedes aegypti, domestic day-bit-
ing mosquitoes. Dengue virus induces 
clinical illness, which ranges from a 
nonspeciﬁ   c viral syndrome (dengue 
fever [DF]) to severe and fatal hem-
orrhagic disease (dengue hemorrhagic 
fever [DHF]). DF/DHF occurs primar-
ily in tropical and subtropical areas of 
the world. Domestic dengue virus in-
fection occurs in >100 countries; >2.5 
billion persons live in these areas. Ap-
proximately 100 million cases of DF, 
500,000 cases of DHF, and several 
thousand deaths occur annually world-
wide (1). During the past decades, 
dengue virus has emerged in south-
ern Asia; DF/DHF epidemics have 
occurred in Bhutan, India, Maldives, 
Bangladesh, and Pakistan (2–4).
From August through November 
2006, the number of febrile patients 
increased in 4 major hospitals in the 
Terai region of Nepal: Nepalgunj 
Medical College, Bheri Zonal Hospi-
tal in Nepalgunj, Tribhuban Hospital 
in Dang, and Narayani subregional 
hospital in Birgunj. Patients with se-
vere symptoms were referred to Sukr-
araj Tropical and Infectious Disease 
Hospital, Kathmandu, for diagnosis 
and treatment. The clinical features 
in most patients were consistent with 
signs of DF, but some patients showed 
signs (high fever, rash, ecchymosis, 
epistaxis, positive tourniquet test, liv-
er dysfunction, and thrombocytopenia 
[platelet count <100,000/mm3]) con-
sistent with the World Health Organi-
zation (WHO) deﬁ  nition of DHF. As-
cites and plural effusion developed in 
2 patients. Blood specimens were col-
lected from all patients at the time of 
admission to the local hospitals. Par-
ticle agglutination (PA) assay (Pentax 
Ltd, Tokyo, Japan) (5) and immuno-
globulin (Ig) M–capture ELISA (Den-
gue/JE IgM Combo ELISA kit, Panbio 
Ltd, Brisbane, Queensland, Australia) 
were performed. Dengue virus–specif-
ic IgM was detected in 11 patients who 
had fever, headache, and rash (Table). 
Each of these patients had negative 
514  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 3, March 2008
Table. Clinical and laboratory data for 11 patients admitted to hospitals and diagnosed with dengue fever or dengue hemorrhagic
fever, Nepal, 2006* 
Patient
age, y/Sex
Month
admitted Location
Initial
diagnosis
Travel
history
Clinical signs and 
symptoms Selected laboratory and other test results 
20/M Sep Kathmandu DF Yes Fever, headache, 
nausea
Hb 15.4 g/dL; TLC 10,500/mm
3;
Plt 185,000/mm
3; blood culture for 
salmonellae negative; ALT 38 IU/L 
27/F Sep Bardiya Viral fever No Fever, headache, 
vomiting
TLC 5,600/mm
3; blood culture for 
salmonellae negative 
3/M Sep Salayan Encephalitis No Fever, vomiting, 
convulsions
Widal negative; TLC 4,700/mm
3
13/M Oct Sindhuli Typhoid 
fever
No Fever, headache Widal negative; TLC 4,500/mm
3; blood 
culture for salmonellae negative; Brucella
antigen negative; chest radiograph normal 
22/M Oct Birgunj DHF No Fever, headache, 
vomiting, ascites 
Bil 0.8 mg/dL; ALT 80 IU/L; Plt 22,000/mm
3;
chest radiograph normal 
55/F Oct Dang DF No Fever, headache, 
muscular pain 
Plt 51,000/mm
3; TLC 7,600/mm
3; MP 
negative; ESR 20 mm/h; Bil 0.7 mg/dL 
22/F Oct Birgunj Viral fever  No Fever, headache,  
body ache 
Brucella negative; Widal negative;
TLC 5,600/mm
3
13/M Nov Dang DF No Fever, headache, 
rashes
Plt 95,000/mm
3; TLC 4,700/mm
3;
Hb 13.1 g%; Bil 0.8mg/dL; ALT 26 IU/L 
35/F Nov Birgunj DHF No Fever, headache, 
bruises; tourniquet: 
positive
Bil 0.81mg/dL; Plt 31,000/mm
3;
PT 2 min 30 s (control 14) 
40/M Nov Birgunj DF No Fever, headache, 
rashes
ALT 127IU/L; Plt 110,000 /mm
3;
PCV 38.8%;TLC 5,500/mm
3;
ultrasonography liver size, 16.8 cm 
42/M Nov Dang DF No Fever, headache, 
rashes
Bil 0.7 mg/dL; Widal test negative;
TLC 6,800/mm
3; Plt 164,000/mm
3
*Blood specimens were collected at time of hospital admission. Diagnosis was confirmed by using immunoglobulin M–capture ELISA. DF, dengue fever; 
Hb, hemoglobulin;TLC, total leukocyte count; Plt, platelets; ALT, alanine aminotransferase; DHF, dengue hemorrhagic fever Bil, bilirubin; MP, malaria 
parasites; ESR, erythrocyte sedimentation rate; PT, prothrombin time; PCV, packed cell volume. LETTERS
results for Japanese encephalitis vi-
rus–speciﬁ  c IgM. Of the 11 patients, 
10 had no history of travel to India or 
other dengue-endemic countries. DF or 
DHF was initially diagnosed for 7 pa-
tients, and viral encephalitis, typhoid 
fever, or viral fever was diagnosed for 
others without serologic tests. Reverse 
transcription–PCR and virus isolation 
were performed at Institute of Tropi-
cal Medicine, Nagasaki University, 
Nagasaki, Japan, but the dengue virus 
genome was not detected, and no virus 
was isolated, likely because sample 
collection was delayed and the sample 
was transported to Japan in a deterio-
rated condition.
DF/DHF have been considered 
to be a possible public health threat 
to Nepal because DF/DHF epidemics 
have occurred recently in India and 
Pakistan, which reported several thou-
sand cases and >100 deaths (6). The 
ﬁ  rst DF case in Nepal was reported 
in 2004 (7). Further, the ﬁ  rst DENV-
2 strain of Nepal origin was isolated 
from a Japanese traveler who visited 
Nepal and in which DF developed af-
ter the patient returned to Japan. The 
isolated DENV-2 (GenBank accession 
no. AB194882) was 98% homologous 
with DENV-2 isolated in India (8). The 
prevalence of dengue virus antibody 
was reported to be 10.4% in the south-
western region of Nepal (9). These 
reports suggest that dengue virus has 
been circulating in Nepal for several 
years. Thus, DF/DHF has likely been 
misdiagnosed and illness caused by 
dengue virus underestimated in Ne-
pal. In contrast, Japanese encephali-
tis has been a public health problem 
in southwestern region of Nepal, and 
large epidemics have occurred almost 
every year since 1978 (10). Nepal has 
no dengue surveillance programs, and 
health professionals do not usually 
consider dengue as a differential diag-
nosis.
The emergence occurred in the 
lowland Terai belt region, which bor-
ders the state of Bihar, India. The Ae-
des mosquito is known to persist in 
this region. The emerging DENV-2 
is likely to have been introduced into 
Nepal from India.
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Human 
Tuberculosis 
Caused by 
Mycobacterium 
bovis, Taiwan 
To the Editor:  Mycobacterium 
bovis is one of the causative agents 
of tuberculosis (TB) in humans and 
animals. Drinking unpasteurized milk, 
eating undercooked meat, and close 
contact with infected animals are the 
main sources of infection for humans. 
Currently, 119 M. bovis spoligotypes 
are contained in the fourth internation-
al spoligotyping database (SpolDB 4) 
and are categorized into 3 main sublin-
eages corresponding to ST prototypes 
482, 683, and 479 (1). 
Although an M. bovis surveillance 
program for farm animals has been 
implemented by the Taiwan Council 
of Agriculture, no surveillance system 
exists for human TB cases caused by 
M. bovis. To monitor the epidemiol-
ogy of M. bovis in domestic animals, 
a regular tuberculin skin test (TST) 
is compulsory for cattle and sheep 
and optional for deer in Taiwan (2). 
In 2005, screening of Mycobacterium 
spp. infections by TST was performed 
for 111,412 cattle and 73,396 caprint 
and ovine herds, of which 188 (0.17%) 
and 148 (0.2%), respectively, were 
positive (2). We used spacer oligo-
nucleotide typing (spoligotyping) and 
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